Key Takeaways
Pelthos Therapeutics Inc. (PTHS) reported a first-quarter loss of $3.09 per share, a 22.75 percent upside surprise that also narrowed from prior-year results.
"In the first quarter of 2026, we continued to build momentum for ZELSUVMI, driven by the expansion of our sales force and focused commercial execution," Scott Plesha, CEO of Pelthos, said in a statement. "The increase in dispensed units positions us well for continued growth in the second quarter and beyond."
The biomedical firm posted revenue of $10.91 million, beating the Zacks Consensus Estimate by over 12 percent. This compares to zero revenue in the same quarter last year, when the company reported a loss of $3.20 per share. The beat was driven by the company’s lead product, ZELSUVMI, which saw sales increase 17 percent from the previous quarter.
While shares have underperformed the market this year, the better-than-expected results signal its commercial strategy may be gaining traction. Investors are now watching for continued growth in the second quarter, for which consensus estimates project revenues of $15.08 million.
The main driver of the first-quarter beat was Pelthos' lead product, ZELSUVMI, a topical treatment for molluscum contagiosum. Net product revenue for the drug came in at $10.7 million, a 17 percent increase from the fourth quarter of 2025.
The company reported that 7,884 units were prescribed by over 3,200 unique prescribers during the quarter. According to the company's press release, dispensed units in April reached 3,776, with total units since launch surpassing 20,000. Pelthos also plans to commercialize two other products, XEPI and XEGLYZE, in early and mid-2027, respectively.
Despite the strong quarter, Pelthos Therapeutics stock has lost about 16.1 percent since the beginning of the year, compared to the S&P 500's 8.8 percent gain.
Ahead of the earnings release, the estimate revision trend was mixed, translating to a Zacks Rank #3 (Hold). This suggests the stock is expected to perform in line with the market in the near future. Another company in the Medical - Biomedical and Genetics industry, CervoMed Inc. (CRVO), has yet to report its quarterly results.
The strong performance of ZELSUVMI suggests the company's commercialization strategy is effective, a positive signal for its upcoming product launches in 2027. Investors will be watching the company's next earnings call for updates on sales momentum and progress on its pipeline.
This article is for informational purposes only and does not constitute investment advice.
